Figure 2 | British Journal of Cancer

Figure 2

From: A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer

Figure 2

(A) Mean quality-adjusted PFS for patients with wild-type KRAS mCRC receiving panitumumab+BSC or BSC alone. (B) Mean quality-adjusted OS for patients with wild-type KRAS mCRC receiving panitumumab+BSC or BSC alone. BSC=best supportive care; mCRC=metastatic colorectal cancer; OS=overall survival; PFS=progression-free survival; Q-TWiST=quality-adjusted time without symptoms of disease or toxicity of treatment.

Back to article page